Reference
ADAKVEO (Crizanlizumab): Important Safety Information from Novartis Ireland Ltd as approved by the HPRA (14.02.23) Internet Document : 15 Feb 2023. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/adakveo-(crizanlizumab)-important-safety-information-from-novartis-ireland-ltd-as-approved-by-the-hpra-(14.02.23)&id=80d11326-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
Crizanlizumab not superior to placebo and has higher rates of grade ≥3 AEs. Reactions Weekly 1945, 2 (2023). https://doi.org/10.1007/s40278-023-34083-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-34083-6